[Patient with bone metastasis of breast cancer who were improved by weekly DXR/TXT therapy].
The patient was a 57-year-old female with the main complaint of left chest pain and gait disturbance. Multiple bone metastases were observed in the vertebral and pelvic bone. Pathological pressure fracture, stegnosis of the spinal canal and edematous changes in the spinal nerves, especially in the 4th and 5th thoracic vertebrae, were observed. The clinical pathological status was T4cN1M1b, OSS Stage IV. After 4 cycles of weekly doxorubicin (DXR) (20 mg/body)/docetaxel (TXT) (40 mg/body) therapy (day 1, day 8, day 15, 1-week recovery period) were given to the patient, CA15-3 had decreased from 1,200 U/ml to 28 U/ml. The histopathological effect was judged to be Grade 2. Thereafter, ICTP was increased to 12.7 ng/ml and after 2 cycles of the weekly DXR/TXT therapy (day 1, day 8, 2-week recovery period) had been added, the patient was able to walk. MRI of the thoracic vertebrae showed that the foci of bone metastasis had improved 9 months after the treatment with chemotherapeutics, and good PS was maintained. No serious adverse reactions were observed with the weekly DXR/TXT therapy. Therefore, weekly DXR/TXT therapy is considered to be effective in treating patients with bone metastasis.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000556:secondary*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000601:surgery; D018270:Carcinoma, Ductal, Breast / Q000188:drug therapy* / Q000556:secondary* / Q000601:surgery; D000077143:Docetaxel; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015412:Mastectomy, Segmental; D008875:Middle Aged; D017239:Paclitaxel / Q000008:administration & dosage / Q000031:analogs & derivatives*; D043823:Taxoids
D043823:Taxoids; D000077143:Docetaxel; D004317:Doxorubicin; D017239:Paclitaxel